Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single-Arm, Multi-center Phase Ib/II Study to Evaluate the Safety and Efficacy of INCB054828 in Combination With Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer With FGFs/FGFRs Genetic Aberration.

NCT05529667 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT05529667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05529667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single-Arm, Multi-center Phase Ib/II Study to Evaluate the Safety and Efficacy of INCB054828 in Combination With Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer With FGFs/FGFRs Genetic Aberration.
Lead sponsor
Yonsei University
Phase
Phase 1/2
Overall status
Completed
Start date
May 27, 2019
Completion date
August 30, 2023
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fibroblast growth factors (fgfs)/fibroblast growth factor receptors (fgfrs) genetic aberration gastric cancer, incb054828, paclitaxel